0
Cardiovascular Disease |

Three Years Effects of Adaptive Servo-Ventilation in Stable Congestive Heart Failure

Hitoshi Koito*, MD; Munmitsu Ohtagaki, MD; Nobuyuki Hayashi, MD; Miwako Satoh, MD
Author and Funding Information

Misugikai Otokoyama Hospital, Yawata, Kyoto, Japan


Chest. 2012;142(4_MeetingAbstracts):111A. doi:10.1378/chest.1382020
Text Size: A A A
Published online

Abstract

SESSION TYPE: Heart Failure Posters

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: The purpose of this study is to evaluate three years effects of adaptive servo-ventilation (ASV) on sleep apnea (SA), quality of life (QOL) and cardiac function in patients with stable congestive heart failure (CHF) and SA treated with bi-level positive airway pressure (PAP).

METHODS: Subjects were 8 patients with CHF and SA who were treated with bi-level PAP and converted to ASV. We performed pulse oxymetory, nasal airflow, chest and abdominal wall motion and electrocardiographic monitoring system (TEIJIN, Morpheus C) before bi-level PAP (B), on room air (Control;C), and after 1 year (1Y) and 3 years (3Y) of domiciliary ASV. New York Heart Association (NYHA) functional class and minimum symptom appearing activity (METs) by specific activity scale, chest rentogenogrm, Doppler echocardiography, respiratory function and urinary noradrenaline (NAd) were compared before and after 1 year and 3 years of domiciliary ASV.

RESULTS: Apnea hypopnea index (AHI;/h) improved from 32(B) and 23(C) to 6(1Y) and 7(3Y). Central apnea index (CAI;/h) decreased from 10.2(B) and 6.7(C) to 0.5(1Y) and 0.2(3Y). Oxygen desaturation index more than 4% (4%ODI;/h) improved from 27(C) to 4(1Y) and 10(3Y). NYHA and METs had improved tendency in 3Y from 2.6(B) and 2.4(C) to 2.4(1Y) and 2.3(3Y), and from 4.3(C) to 4.4(1Y) and 4.8(3Y), respectively. Cardio-thoracic ratio (CTR;%) reduced from 55(B) and 55(C) to 52(1Y) and 52(3Y). End-systolic left ventricular diameter decreased in 1Y. Percent fractional shortening (%FS;%) and ejection fraction (EF;%) improved from 29(B) and 28(C) to 35(1Y) and 34(3Y), and 53(B) and 53(C) to 62(1Y) and 60(3Y), respectively. Mitral regurgitation and estimated right ventricular systolic pressure (RVsP;mmHg) improved in 3Y. Urinary NAd improved in 3Y from 156(C) to 78(3Y). Percent vital capacity (%) improved from 93(C) to 98(1Y) and 100(3Y).

CONCLUSIONS: These results suggest that 3 years of domiciliary ASV is useful for improving SA, QOL and cardiac function in patients with stable CHF.

CLINICAL IMPLICATIONS: Three years of domiciliary ASV is the useful therapy for treating stable CHF.

DISCLOSURE: The following authors have nothing to disclose: Hitoshi Koito, Munmitsu Ohtagaki, Nobuyuki Hayashi, Miwako Satoh

No Product/Research Disclosure Information

Misugikai Otokoyama Hospital, Yawata, Kyoto, Japan

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543